Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD, reviews the changes in the screening and diagnosis of primary biliary cholangitis in the recently published CDLF guidelines, as well as when a primary care physician should refer a patient to a specialist to assess disease presence.
Data from a phase 2 substudy of retatrutide indicates use could reduce liver fat content and contribute to resolution of NAFLD in people with NAFLD and obesity.
BOS-580 is an investigational, proprietary, long-acting fibroblast growth factor 21 analog as a monthly and bi-weekly treatment for patients with NASH.
At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.
The treatment, developed by Intercept Pharmaceuticals, could not be approved in its present form, according to the CRL and any resubmission of the treatment for patients with NASH would require at least the successful completion of the long-term outcomes phase of the REGENERATE study.
Experts in hepatology share their approach to diagnosing primary biliary cholangitis and discuss the use of liver biopsies in diagnosis.
Steven Flamm, MD, FAASLD, FACG, reviews the disease burden of primary biliary cholangitis on the patient and their family. He also comments on the impact PBC has on a patient’s mental health.
Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.
An analysis of US adults suggests MAFLD affects the Hispanic population at a higher prevalence relative to Black adults and White adults.
Experts in hepatology discuss disease progression of PBC and the long-term complications patients may experience.
David Victor III, MD, comments on the risk factors for PBC and the importance of educating the patient about the disease.
The point prevalence per 100,000 people at the conclusion of the study was 71.8 for autoimmune hepatitis, 38.5 for primary biliary cholangitis, and 11.0 for primary sclerosing cholangitis.
For individuals with hepatitis C virus infections, 52.5% of deaths were deemed attributable to the infection.
The approval makes odevixibat the second IBAT inhibitor approved for the rare genetic disease, with capability to benefit both liver damage and itch symptoms.
Patients with autoimmune hepatitis who were positive for antimitochondrial antibodies and evidence of non-specific bile duct injury had a higher risk of progressing to cirrhosis.
Edward Mena, MD, reviews the classification and diagnosis of PBC considering the change from the term “cirrhosis” to “cholangitis.”
Sonal Kumar, MD, MPH, provides an overview of primary biliary cholangitis (PBC) and its recent increase in prevalence, as well as common signs and symptoms.
A cascade-of-care analysis of the country's largest tribally-operated health system showed clear gaps in progressing patients with HCV from diagnosis to completed treatment.
The IBAT inhibitor will receive an FDA decision by next week. Ovchinsky reviews its supporting data for benefitting patient pruritus, sleep, and liver bile acid levels.
An emerging drug class is proving viable for burdensome symptoms, as well as liver failure, in pediatric patients with the rare inherited disease.
There was an association between NAFLD in the South-Asian population and diabetes mellitus, hypertension, dyslipidemia, general obesity, central obesity and metabolic syndrome.
The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.
In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.
There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.
The genetic rare disease is characterized by a greater risk of premature mortality and worsened quality of life. Emerging IBAT inhibitors are helping address both issues.
